Comparing a new rotigotine patch with Neupro for Parkinson's disease
Part of Brain & nervous system clinical trials.
This study tests whether a new version of the rotigotine patch (a medicine given through the skin) sticks well and is safe compared to the already-approved Neupro patch. It might help people with Parkinson's who need a reliable way to take their medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 30 years or older.
- You have been diagnosed with Parkinson's disease and are at a moderate stage (able to walk and stand without help).
- You have not taken a dopamine agonist (like Mirapex, Requip, or Neupro) in the last month, or you're willing to stop taking one during the study.
- Your thinking and memory are generally good (no major cognitive issues).
- You are able to wear a skin patch and avoid swimming, bathing, or sauna on patch application days.
- You agree to use reliable birth control during the study and for 30 days after, if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a skin patch called rotigotine to see if it is safe for people with ADPKD. It may help with blood pressure control, but you cannot have advanced kidney failure or certain other health issues.
This trial tests if adding a rotigotine patch to your usual rivastigmine treatment can help with symptoms of Alzheimer's. It is for people with mild to moderate Alzheimer's who have been stable on rivastigmine for at least 3 months.
This trial tests an experimental drug called RO7568282 to see if it is safe and can help with early Parkinson's disease symptoms. It is for people who have been taking a stable dose of levodopa alone for at least two months.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This study tests whether a new skin patch, DM1001, is safe and how well the body tolerates it. It is for healthy adults who want to help find out if this patch could be used for future treatments.
This study tests a new single-dose treatment for Parkinson's disease to see if it can help reduce 'off' time—when medication wears off and symptoms return. It is for people who experience motor fluctuations and are already on a stable medication routine.
Hear when a new Idiopathic Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.